Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE
- Publication Information:
Publication: 2015- : Abingdon, Oxford : Taylor & Francis
Original Publication: London : Ashley Publications Ltd., c2001-
- Subject Terms:
Immunoglobulin E*/
immunology;
Antibodies, Anti-Idiotypic/
*therapeutic use ;
Drug Discovery/
*methods ;
Vaccines, Conjugate/
*therapeutic use;
Animals ;
Antibodies, Anti-Idiotypic/
immunology ;
Antibodies, Monoclonal/
immunology ;
Antibodies, Monoclonal/
therapeutic use ;
Antibodies, Monoclonal, Humanized/
immunology ;
Antibodies, Monoclonal, Humanized/
therapeutic use ;
Asthma/
drug therapy ;
Asthma/
immunology ;
Clinical Trials as Topic/
methods ;
Drug Discovery/
trends ;
Humans ;
Hypersensitivity/
drug therapy ;
Hypersensitivity/
immunology ;
Omalizumab/
immunology ;
Omalizumab/
therapeutic use ;
Vaccines, Conjugate/
immunology ;
Vaccines, Subunit/
immunology ;
Vaccines, Subunit/
therapeutic use - Abstract:
Introduction: Given the multifaceted effector functions of IgE in immediate hypersensitivity, late-phase reactions, regulation of IgE receptor expression and immune modulation, IgE antibodies have long represented an attractive target for therapeutic agents in asthma and other allergic diseases. Effective pharmacologic blockade of the binding of IgE to its receptors has become one of most innovative therapeutic strategies in the field of allergic diseases in the last 10 years. Areas covered: The latest strategies targeting IgE include the development of a therapeutic vaccine, able to trigger our own immune systems to produce therapeutic anti-IgE antibodies, potentially providing a further step forward in the treatment of allergic diseases. The aim of this review is to discuss the discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. Expert opinion: Outside the area of development of humanized anti-IgE monoclonal antibodies, the research field of therapeutic IgE-targeted vaccines holds potential benefits for the treatment of allergic diseases. However, most of the experimental observations in animal models have not yet been translated into new treatments and evidence of human efficacy and safety of this new therapeutic strategy are still lacking.
- Contributed Indexing:
Keywords: IgE; adjuvants; allergy; anti-IgE; asthma; omalizumab; vaccine; virus-like particles
- Accession Number:
0 (Antibodies, Anti-Idiotypic)
0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (Vaccines, Conjugate)
0 (Vaccines, Subunit)
0 (anti-IgE antibodies)
2P471X1Z11 (Omalizumab)
37341-29-0 (Immunoglobulin E)
- Publication Date:
Date Created: 20170131 Date Completed: 20170719 Latest Revision: 20181202
- Publication Date:
20221213
- Accession Number:
10.1080/14712598.2017.1289172
- Accession Number:
28132528
No Comments.